R 102380
Latest Information Update: 20 May 2003
At a glance
- Originator Sankyo
- Class Antihyperglycaemics; Thiazolidinediones
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 20 May 2003 No development reported - Preclinical for Diabetes mellitus in Japan (unspecified route)
- 15 Feb 2000 Preclinical development for Diabetes mellitus in Japan (Unknown route)